Skip Navigation LinksHome > December 2013 - Volume 40 - Issue 6 > Growth Arrest–Specific Protein 6 Attenuates Neutrophil Migra...
Shock:
doi: 10.1097/SHK.0b013e3182a588c1
2013 New Investigator Award Competition

Growth Arrest–Specific Protein 6 Attenuates Neutrophil Migration and Acute Lung Injury in Sepsis

Giangola, Matthew D.*; Yang, Weng-Lang*†; Rajayer, Salil R.; Nicastro, Jeffrey*; Coppa, Gene F.*; Wang, Ping*†

Editor's Choice
Collapse Box

Abstract

ABSTRACT: Sepsis is an acute inflammatory condition that can result in multiple organ failure and acute lung injury. Growth arrest–specific protein 6 (Gas6) is a broad regulator of the innate immune response involved with the nuclear factor κB signaling pathway. We hypothesized that Gas6 could have a protective role in attenuating the severity of acute lung injury and sepsis. Male mice were subjected to sepsis by cecal ligation and puncture (CLP) after which recombinant murine Gas6 (rmGas6; 5 μg/mouse) or normal saline (vehicle) was administered intravenously. Blood and lung tissues were collected at 20 h after CLP for various measurements. Treatment with rmGas6 significantly reduced serum levels of the injury markers aspartate aminotransferase, alanine aminotransferase, and lactate dehydrogenase, as well as proinflammatory cytokines interleukin 6 (IL-6) and IL-17, compared with the vehicle group (P < 0.05). The parenchyma of the lungs damaged by CLP was attenuated by rmGas6 treatment. Lung mRNA levels of tumor necrosis factor α, IL-1β, IL-6, IL-17, and macrophage inflammatory protein 2 (MIP-2) were decreased by 60%, 86%, 82%, 93%, and 82%, respectively, with rmGas6 treatment as determined by real-time reverse transcriptase–polymerase chain reaction (P < 0.05). The degradation of IκB-α induced by CLP in the lungs was inhibited by rmGas6 treatment. The number of neutrophils and myeloperoxidase activity in the lungs were significantly reduced in the rmGas6 group. Moreover, rmGas6 reduced the in vitro migration of differentiated human promyelocytic HL60 cells by 64%. Finally, the 10-day survival rate of mice subjected to CLP was increased from 31% in the vehicle group to 67% in the rmGas6 group (P < 0.05). Thus, Gas6 has potential to be developed as a novel therapeutic agent to treat patients with sepsis and acute lung injury.

© 2013 by the Shock Society

Follow Us

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.